In summary, DGM inhibits the alveolar epithelial cell EMT process by inhibiting the TGF-β1/Smad signaling pathway in vitro, and slows the development of pulmonary fibrosis in vivo by reducing lung inflammation, improving lung function, and reducing remodeling of the ECM. The gene discussed is TGFB1; the disease is pulmonary fibrosis.